Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways Plc (Nasdaq: CMPS) is advancing innovative mental health solutions through its COMP360 psilocybin therapy program. This page provides centralized access to official company announcements, clinical trial updates, and strategic partnership developments.
Investors and researchers will find timely updates on regulatory progress, including FDA Breakthrough Therapy designations and international clinical trials. All content is curated to support informed analysis of the company's progress in treatment-resistant depression and related mental health conditions.
Key focus areas include therapy development milestones, healthcare collaboration models, and intellectual property advancements. Resources are organized to help track the company's evidence-based approach to psychedelic-assisted therapies within rigorous clinical frameworks.
Bookmark this page for direct access to primary source materials about CMPS's work in mental health innovation. Visit regularly to stay current with developments in this pioneering sector of biotechnology.
Compass Pathways (NASDAQ: CMPS) has completed recruitment for its COMP005 phase 3 trial evaluating COMP360, a synthetic psilocybin treatment for treatment-resistant depression (TRD). Final participants are completing pre-dosing activities, including antidepressant medication washout where necessary.
The trial is part of the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Top-line results for the 6-week primary endpoint are expected in late Q2 2025, while 26-week data will be available after all participants complete part A of the COMP006 trial, expected in second half 2026.
COMP360 is being investigated as a potential first-in-class psilocybin treatment for mental health conditions, administered with psychological support. TRD affects patients who don't respond adequately to at least two different treatments, with up to one-third of depression patients failing multiple treatment attempts.
Compass Pathways (NASDAQ: CMPS) has published results from its COMP004 study, a 52-week observational follow-up of Phase 2 trials evaluating COMP360 psilocybin for treatment-resistant depression (TRD). The study demonstrated that a single 25mg dose of COMP360 maintained antidepressant effects longer compared to lower doses.
Key findings show the median time to depressive event was 92 days for the 25mg group, versus 83 days (10mg) and 62 days (1mg). A post-hoc analysis revealed even more substantial differences, with 189 days for the 25mg group compared to 43 days (10mg) and 21 days (1mg).
The treatment was generally well-tolerated, with three participants reporting treatment emergent serious adverse events deemed unrelated to the study drug. The company expects top-line data from its ongoing Phase 3 COMP005 trial in Q2 2025, with 26-week COMP006 data anticipated in H2 2026.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its upcoming participation in the Stifel Virtual CNS Forum. The company's management will deliver a presentation on March 18th, 2025 at 11:30 am ET.
The presentation will be available through a live audio webcast on the 'Events' page within the Investors section of Compass's website. Interested parties can access a replay of the webcast for up to 30 days after the event.
Compass Pathways (NASDAQ: CMPS) reported its Q4 and full-year 2024 financial results, highlighting ongoing progress in its clinical trials. The company's Phase 3 COMP005 trial for treatment-resistant depression (TRD) remains on schedule, with top-line data expected in Q2 2025.
Financial results show a net loss of $155.1 million ($2.30 per share) for 2024, compared to $118.5 million in 2023. R&D expenses increased to $119.0 million from $87.5 million, while G&A expenses rose to $59.2 million from $49.4 million.
The company's cash position stood at $165.1 million as of December 31, 2024, with an additional $140.4 million net cash raised in Q1 2025. Full-year 2025 net cash used in operating activities is projected between $120-145 million, with funding sufficient through the planned COMP006 26-week data readout in H2 2026.
Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 3rd, 2025, at 1:10 pm ET.
Investors and interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS), a biotechnology company focused on mental health innovation, has announced it will release its Q4 and full-year 2024 financial results on February 27th, 2025. The company will host a conference call at 8:00 AM ET (1:00 PM UK) on the same day to discuss results and provide updates on recent developments. Investors can access the call through pre-registration, and a live webcast will be available on the company's website. The webcast recording will remain accessible for 30 days in the Investors section.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a presentation on February 12th, 2025, at 8:40 am ET.
Interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS) has appointed Steve Levine, M.D., as Chief Patient Officer in a newly created executive role. Dr. Levine, who has been with Compass since 2020 as Senior Vice President of Patient Access, will focus on embedding patient-centric strategies across the organization and ensuring treatments address unmet clinical care needs.
Dr. Levine is a board-certified psychiatrist with extensive experience in healthcare innovation and access. He previously founded Actify Neurotherapies, developing care delivery models for interventional psychiatry treatments. His academic background includes training at New York-Presbyterian Hospital/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. He currently serves as an adjunct professor at Rutgers Medical School.
Compass Pathways (NASDAQ: CMPS) has announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (ADSs) and pre-funded warrants for up to 11,044,720 ADSs. Each ADS and pre-funded warrant includes an ADS Warrant with an exercise price of $5.796, representing a 40% premium to the last sale price.
The offering price is set at $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and ADS Warrant. The offering, led by Deep Track Capital, is expected to generate gross proceeds of approximately $150 million, potentially reaching $353 million if all ADS Warrants are exercised.
The proceeds will fund ongoing Phase 3 trials in treatment-resistant depression (COMP005 and COMP006), with data expected in Q2 2025 and H2 2026, respectively. Additionally, funds will accelerate a late-stage PTSD development program and support working capital needs.
Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, announced its inclusion in the NASDAQ Biotechnology Index (NBI), effective December 23, 2024. The NBI tracks biotechnology and pharmaceutical companies listed on NASDAQ, using a modified market capitalization weighted methodology. Index membership requires companies to meet specific criteria including minimum market capitalization and average daily trading volume. The index undergoes annual reconstitution in December.
FAQ
What is the current stock price of Compass Pathways Plc (CMPS)?
What is the market cap of Compass Pathways Plc (CMPS)?
